PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.

Autor:	Sinha S; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA. ssinha@sbpdiscovery.org.; NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA, USA. ssinha@sbpdiscovery.org., Vegesna R; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA., Mukherjee S; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA., Kammula AV; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA.; University of Maryland, College Park, MD, USA., Dhruba SR; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA., Wu W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Kerr DL; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Nair NU; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA., Jones MG; Center for Computational Biology, University of California, Berkeley, Berkeley, CA, USA.; Department of Electrical Engineering and Computer Science, University of California, Berkeley, Berkeley, CA, USA.; Integrative Program in Quantitative Biology, University of California, San Francisco, San Francisco, CA, USA.; Whitehead Institute, Cambridge, MA, USA., Yosef N; Center for Computational Biology, University of California, Berkeley, Berkeley, CA, USA.; Department of Electrical Engineering and Computer Science, University of California, Berkeley, Berkeley, CA, USA., Stroganov OV; Rancho BioSciences, San Diego, CA, USA., Grishagin I; Rancho BioSciences, San Diego, CA, USA.; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA., Aldape KD; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Blakely CM; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Jiang P; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA., Thomas CJ; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Benes CH; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Bivona TG; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Chan Zuckerberg Biohub Investigator, San Francisco, CA, USA., Schäffer AA; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA., Ruppin E; Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, USA. eytan.ruppin@nih.gov.
Jazyk:	angličtina
Zdroj:	Nature cancer [Nat Cancer] 2024 Jun; Vol. 5 (6), pp. 938-952. Date of Electronic Publication: 2024 Apr 18.
DOI:	10.1038/s43018-024-00756-7
Abstrakt:	Tailoring optimal treatment for individual cancer patients remains a significant challenge. To address this issue, we developed PERCEPTION (PERsonalized Single-Cell Expression-Based Planning for Treatments In ONcology), a precision oncology computational pipeline. Our approach uses publicly available matched bulk and single-cell (sc) expression profiles from large-scale cell-line drug screens. These profiles help build treatment response models based on patients' sc-tumor transcriptomics. PERCEPTION demonstrates success in predicting responses to targeted therapies in cultured and patient-tumor-derived primary cells, as well as in two clinical trials for multiple myeloma and breast cancer. It also captures the resistance development in patients with lung cancer treated with tyrosine kinase inhibitors. PERCEPTION outperforms published state-of-the-art sc-based and bulk-based predictors in all clinical cohorts. PERCEPTION is accessible at https://github.com/ruppinlab/PERCEPTION . Our work, showcasing patient stratification using sc-expression profiles of their tumors, will encourage the adoption of sc-omics profiling in clinical settings, enhancing precision oncology tools based on sc-omics. (© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink